. 2021 Jun 30;33(3):289–301. doi: 10.21147/j.issn.1000-9604.2021.03.01

Table 4. Treatment strategies for newly-diagnosed mantle cell lymphoma.

Stratification	Treatment section	Category recommendations	Category II recommendations
ASCT, autologous stem cell transplantation; BR, bendamostine and rituximab; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; R-DHAP, rituximab, dexamethasone, cisplatin and cytarabine; R-hyper-CVAD, R-hyper-CVAD/MA, rituximab, cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate and cytarabine; VR-CVP, bortezomib, rituximab, cyclophosphamide, doxorubicin and prednisone.
Fit for ASCT	Induction	Clinical trial Rituximab plus high-dose Ara-C-based regimen (R-CHOP/R-DHAP, R-mega CHOP/R-high-dose-Ara-C, R-HyperCVAD, etc.) (Level 1B evidence)	BR/R-high-dose-Ara-C (Level 2A evidence)
	Consolidation	ASCT (Level 1B evidence)
	Maintenance	Rituximab (Level 1A evidence)	Observation (Level 2A evidence)
Unfit for ASCT	Induction	Clinical trial Rituximab plus chemotherapy (R-CHOP, BR, VR-CAP, etc.) (Level 2A evidence)	R² (Level 2A evidence)
	Maintenance	Rituximab (Level 1A evidence)